Analysts' average 12-month price target for LifeMD is $7.2.
Get informed when a big investor buys or sells
+ Follow$3.05
5 analysts in the last 4 months
High: $10 | Low: $5
No recommendations in the last 4 months.
LifeMD posts a target price of $7.2. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $7.2 for LFMD means covering analysts, on average, see the stock 136.1% upside of $3.05 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for LFMD's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; LifeMD's other metric pages and overview cover the third.
Judging LifeMD against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $7.2 here, then scan peer and history charts to see if the gap is persistent.